Showing 91 - 98 of 98
Competition is the key to low prices in the pharmaceutical industry. For decades, Americans have benefited from affordable generic versions of brand-name drugs. But now, we stand poised on the wave of a revolution. Biologics, which include lifesaving cancer-treating drugs, can cost hundreds of...
Persistent link: https://www.econbiz.de/10013244008
Fall Saturdays and college football. The March Madness basketball tournament. The NCAA plays an important role in many Americans’ lives. But for decades, the association has justified its restrictions on compensation to student-athletes on the basis of “amateurism.” Those attempts just ran...
Persistent link: https://www.econbiz.de/10013214470
Consumers suffer from high drug prices, which stem in large part from pharmaceutical companies’ anticompetitive games. This essay discusses the crucial role antitrust enforcement agencies can play in addressing pay-for-delay settlements and product hopping and draws lessons from this...
Persistent link: https://www.econbiz.de/10013215870
bad? In a word: everything. The intersection of patent and antitrust law has a long pedigree. For decades, antitrust …’s role in patent-based activity has been acknowledged. Patent licenses are subject to antitrust scrutiny. “Pay for delay … extricated patent-based conduct from antitrust scrutiny. Such a gambit diverged from the longstanding bipartisan approach that …
Persistent link: https://www.econbiz.de/10013215871
SDO policies that permit SEP holders to charge implementers monetary patent royalties, sometimes on terms that are …
Persistent link: https://www.econbiz.de/10014244406
Whenever Congress considers reasonable legislation to lower drug prices, we hear that this will be the "end of innovation." This short piece compares Big Pharma to the boy who cried wolf, offering numerous examples (going back to 1961!) of the industry claiming that legislation will harm innovation
Persistent link: https://www.econbiz.de/10014032610
office in 2017 determined to shake things up. He had strong views on how antitrust should consider patent-related issues in … approach to standard setting organizations that recognizes the potential occurrence of patent holdup. Second, Kanter should … reinstate the 2013 Statement issued by the U.S. Patent and Trademark Office (PTO) and Antitrust Division, from which Delrahim …
Persistent link: https://www.econbiz.de/10013314353
In the area of drug patent settlements, the Third Circuit's ruling in King Drug Co. of Florence v. Smithkline Beechham … decision that ensures a role for antitrust scrutiny of potentially anticompetitive drug patent settlements …
Persistent link: https://www.econbiz.de/10013016075